Primary esophageal melanoma (PEM) is a rare and aggressive malignancy with limited treatment options. Due to its rarity, no standardized guidelines exist for managing oligometastatic recurrence, particularly in resource-limited settings. We present a case of a 60-year-old male with PEM who underwent esophagectomy followed by surgical resection of an adrenal metastasis. Despite the increasing use of immunotherapy, surgical resection remains a viable alternative for oligometastatic recurrence when access to systemic therapies is restricted. This case highlights the feasibility of surgery in achieving long-term disease control in select patients. Further studies are needed to establish evidence-based strategies for treating PEM recurrence in resource-constrained environments.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896786 | PMC |
http://dx.doi.org/10.1093/jscr/rjaf123 | DOI Listing |
J Surg Case Rep
March 2025
Pathology Department, NPO "National Cancer Institute", 33/43 Yulii Zdanovskoi street, Holosiivskyi District, Kyiv 03022, Ukraine.
Primary esophageal melanoma (PEM) is a rare and aggressive malignancy with limited treatment options. Due to its rarity, no standardized guidelines exist for managing oligometastatic recurrence, particularly in resource-limited settings. We present a case of a 60-year-old male with PEM who underwent esophagectomy followed by surgical resection of an adrenal metastasis.
View Article and Find Full Text PDFEur J Surg Oncol
February 2025
Department of Surgery, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK; The Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool, UK. Electronic address:
Background: In management of retroperitoneal sarcoma (RPS), radical resection remains the main facet of curative treatment. While recurrence is common, a clear consensus does not exist around optimal post-operative surveillance and post recurrence management.
Materials And Methods: Patients undergoing resection for RPS over a 10 year period were identified through a prospectively maintained database.
Pancreatic metastases are very rare tumors comprising 2-5 % of all malignant tumors of the pancreas. Colorectal pancreatic metastases are rare - 1.7%.
View Article and Find Full Text PDFLancet Oncol
March 2025
Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
Background: Metastasis-directed therapy by stereotactic body radiotherapy (SBRT) has been shown to improve clinical outcomes in the oligometastatic prostate cancer setting. We aimed to investigate whether short-course androgen deprivation therapy (ADT) and SBRT at all oligometastatic sites versus SBRT alone improves clinical progression-free survival in men with metachronous oligorecurrent hormone-sensitive prostate cancer.
Methods: The RADIOSA study was a single-centre, randomised, open-label, controlled phase 2 trial done in the European Institute of Oncology, IRCCS, Milan, Italy.
Curr Opin Urol
March 2025
Investigation Institute, Clinico San Carlos Hospital.
Purpose Of Review: To review the evidence for metastasis-directed therapy (MDT) in oligometastatic (OM) prostate cancer (PC) and future directions in this clinical setting.
Recent Findings: The indications for radiotherapy in PC have significantly increased over the last decade. The treatment of OM disease has been gaining popularity thanks to new molecular imaging techniques that allow more accurate identification of OM patients who may benefit from MDT.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!